112018-2019 Platinum Partner:

Buyer Scenario

222018-2019 Platinum Partner:

Buyer’s GuideYou are a non-nonsense healthcare executive. You know that your job is to put your hospitals at the top of the lists for healthcare outcomes as today's patients seek out such information when they need hospitalization You take great pride in your hospital system and its quest for continued improvement

You know that your hospitals have been doing "ok" in the area of infection prevention but you have room for improvement.

In order to level the responses for the sellers, we ask that you raise the following issues and ask the following questions. By asking these questions, the judges will benefit as well as they will be listening and scoring the responses as part of the overall scoring.

1. 13 of our hospitals use BioPatch and a Non-Securement Dressing. Why should I change these 13 hospitals to the 3M Tegaderm product? We like the BioPatch just fine.

2. Can you tell me about the education that you will conduct? We have a lot of the BioPatch in inventory. If we decide to switch, are you equipped to educate 13 hospitals? I'm worried about the timing of a roll out.

3. I am concerned about the price of the two kits. I know the nurses don't really mind how much we spend, but it is my job to make the best clinical decisions while observing the price and the impact it will have.

Baylor Business Selling Outside 2019 Seller Scenario

Overview This BBSO builds upon our 2019 Top Gun program concerning Internal Selling where you need to consider the internal selling that your customer contact, the “mobilizer,” may have to do to “sell in” your product. Sellers must understand their mobilizers’ motivations, as well as the other players who may be a part of the mobilizers’ buying centers. Your goal as the seller is to equip your buyer/mobilizer to effectively sell internally and create product acceptance across the organization.

You work for the 3M company, a Fortune 500 organization that operates out of the greater Minneapolis-St. Paul area of Minnesota. 3M Company is a multinational conglomerate comprised of five business areas: Consumer, Electronics and Energy, Health Care, Industrial, and Safety and Graphics. With 90,000 employees worldwide and offering more than 50,000 products, 3M makes up one of the thirty Dow Jones Industrial Average Components. In addition to household brands such as Post-it®, Scotch®, and Nexcare™, 3M specializes in a variety of medical products and supplies.

Your Role and Opportunity As a Medical Solutions Division sales representative for 3M Company covering Texas, you are tasked with targeting and eventually selling to a variety of acute care clients in your territory. Your product portfolio includes I.V. securement devices, medical tapes, and wound care products. In your 3M role, your management has given you a strategic product bucket where 70% of your variable pay is based on selling securement devices. You need to close $500,000 of new business this year in your $3.4M territory.

You have an appointment with Cody Lambert, the division’s clinical resource manager of the Texas Health Resources to discuss the Tegaderm™ CHG Chlorhexidine Gluconate (CHG) I.V. Securement Dressing. Cody will be participating in the upcoming Chief Nursing Officers(CNO) council meeting where the CNO is deciding between two CHG options: (1)Tegaderm™ Chlorhexidine Gluconate (CHG) I.V. Securement Dressing or (2) Biopatch with3M Non-CHG Dressing. Either product can go into the Central Line Dressing Change Kit.Selling either product positively impacts your quota attainment, but your results are muchhigher with option 1 (Biopatch is a competitive antimicrobial disc so you do not make anycommission on it). If you sell in option 1, the opportunity is worth $300,000 to 3M.

Overview Provided to Seller

You have met Cody once before, 6 months ago, and provided a quick product overview. Cody was “all business” in that last meeting so you anticipate Cody will be very focused on preparing for the upcoming CNO meeting. Texas Health Resources Texas Health Resources is one of the largest U.S. faith-based, nonprofit health systems and the largest North Texas system in inpatients and outpatients served. The health system includes Texas Health Physicians Group and hospitals under the banners of Texas Health Presbyterian, Texas Health Arlington Memorial, Texas Health Harris Methodist and Texas Health Huguley. Texas Health has affiliated with numerous organizations providing more than 350 points of access, 24,000 employees and 6,000 physicians. Their vision is "partnering with you for a lifetime of health and well-being." Texas Health has 29 hospital locations - including acute-care, short-stay, behavioral health, rehabilitation and transitional care facilities - that are owned, operated or joint-ventured with Texas Health Resources along with more than 350 outpatient facilities, satellite emergency rooms, surgery centers, fitness centers, imaging centers and other community access points including Texas Health Physician Group clinics, doctors' offices, sleep medicine clinics, and Minute Clinics. The division of THR that you are calling on is comprised of 15 hospitals. Currently, 2 of the 15 hospitals use Tegaderm™ CHG Chlorhexidine Gluconate (CHG) I.V. Securement Dressing. Once the product decision is made, all 15 hospitals will standardize their central line dressing kit to the chosen product. The Product Situation Tegaderm™ CHG Chlorhexidine Gluconate (CHG) I.V. Securement Dressing is the only transparent dressing proven to reduce catheter-related bloodstream infections (CRBSI) and vascular catheter colonization (a bacterial concern). Tegaderm™ gives medical patients an added level of comfort and protection, while simplifying the health care provider’s daily vascular access routine. Tegaderm™ CHG I.V. Securement Dressings provide multiple benefits (infection reduction, securement, site visibility and breathability) into one, easy-to-use product. Your product provides a convenient and reliable solution for securing and monitoring of catheters and other I.V. devices. The advantages of Tegaderm™ CHG Chlorhexidine Gluconate (CHG) I.V. Securement Dressing are its all-in-one dressing/antimicrobial/securement, visibility (the clinicians can see the insertion site), FDA clearance, stronger securement at the site, and one-cent less expensive per central line kit.

Applications of Tegaderm™ CHG I.V. Securement Dressings • Short peripheral I.V. (small, flexible tube placed into a peripheral vein for I.V. therapy such as medication fluids) and midline venous catheters (inserted into one of 3 veins in the arm) • Central venous catheters (subclavian, jugular, femoral and PICCs) (placed into large veins) • Dialysis catheters (for exchanging blood to and from a hemodialysis machine and a patient) • Arterial catheters (used in an artery in intensive care and anesthesia to monitor blood pressure directly & obtain samples for arterial blood gas analysis) • Epidural catheters (very thin, flexible tubes implanted into the spine) • Other percutaneous (needle puncture of the skin) devices Your objective is to sell in option 1 using the information in this case as well as this information:

• You never speak poorly of a competitor’s product but nurses have complained that the Biopatch is difficult to position properly on the I.V. In fact, 3M has research to suggest that almost 2/3 of all Biopatch applications are done incorrectly.

• Option 1 requires stocking a single product whereas Option 2 requires stocking 2 products (the Biopatch, and a securement device or what can be referred to as a dressing).

• The transition from the previous product to the new kit product will take approximately 2 months (they have to “run down” their current inventory).

• You will train all of the nursing staff in the 13 hospitals who are not using Tegaderm™ CHG Chlorhexidine Gluconate (CHG) I.V. Securement Dressing and that training will take approximately 2 months.

Good luck!

© 3M 04/20/2010 Page 1 of 7 106008QA.pdf

3M™ Tegaderm™ CHG Chlorhexidine Gluconate IV Securement Dressing

Commonly Asked Questions

Question: Does the Tegaderm™ CHG gel pad absorb fluid, such as drainage or blood? Answer: Yes. Tegaderm™ CHG Dressing absorbs blood, sweat and exudates. As the gel pad absorbs fluid, it swells and becomes larger in size. Drainage should stay contained within the gel, not leak out beyond the gel pad nor obscure visualization of the site. Tegaderm™ CHG dressing is not designed for absorption of large quantities of blood or drainage. Question: When do I need to change the Tegaderm™ CHG Dressing? Answer: In accordance with current CDC guidelines, transparent adhesive dressings for Central Venous Catheters (CVCs), including PICCs, should be changed when the integrity of the dressing is compromised or “at least weekly for adults and adolescent patients, depending on the circumstances of the individual patient”. One key benefit of Tegaderm™ CHG Dressing is the ability for visual assessment of the catheter site. The dressing should also be assessed daily as part of care and maintenance of the vascular access device. Indications to change the dressing are:

a. There is drainage or bleeding visible outside of the gel pad. b. The dressing becomes loose, soiled or compromised in any way. c. The insertion site is obscured and no longer visible. d. If the dressing gel pad appears to be saturated or overly swollen.

To check for oversaturation, push your finger on the corner of the gel pad, it will not bounce back to the original shape if it has absorbed too much fluid; the indent of your finger will remain after you take your finger away.

e. Every seven (7) days or according to your facility protocol. Question: Can Tegaderm™ CHG Dressing be left on for 10 days? Answer: Tegaderm™ CHG dressing has been shown to effectively inhibit re-growth of skin flora on healthy subjects for up to 10 days. However, consistent with current CDC 2002 Guidelines, the dressings should be changed “at least weekly for

© 3M 04/20/2010 Page 2 of 7 106008QA.pdf

adults and adolescent patients, depending on the circumstances of the individual patient”. Question: Does 25% CHG provide better antisepsis than 2% CHG? Answer: Studies on skin flora of healthy subjects have shown Tegaderm™ CHG Dressing provides effective antimicrobial action. Tegaderm™ CHG dressing has a lower concentration of CHG by weight than BIOPATCH®. While the relative volume of CHG available on patient skin has not been studied, Tegaderm™ CHG dressing has been demonstrated to be as effective, or better, at reducing skin flora on healthy subjects than BIOPATCH®. Question: How does chlorhexidine gluconate work in the Tegaderm™ CHG Dressing gel pad? Answer: CHG is an active antimicrobial component of the Tegaderm™ CHG dressing gel pad. The gel is composed of water, 2% chlorhexidine gluconate and other polymers. The aqueous nature of the gel pad and CHG allow for immediate antimicrobial action upon application to skin. Question: If we use Tegaderm™ CHG Dressing do we still need to use a skin prep? Answer: Yes. According to CDC 2002 Guidelines, disinfect clean skin with an appropriate antiseptic before catheter insertion and during dressing changes. A 2% chlorhexidine-based preparation is preferred. Tegaderm™ CHG dressing is designed to work with any prepping agent. Use of Tegaderm™ CHG dressing has been demonstrated to reduce skin flora counts on healthy subjects to lower levels than can be achieved with skin preps alone. In addition, antimicrobial protection will be provided continuously at the site for up to ten days, whereas no prep claims to have activity past 48 hours. (However, consistent with current CDC 2002 Guidelines, the dressings should be changed “at least weekly for adults and adolescent patients, depending on the circumstances of the individual patient”.) Question: Can I use Tegaderm™ CHG Dressing together with 3M™ Cavilon™ No Sting Barrier Film? Answer: Yes. Cavilon™ No Sting Barrier Film is compatible with Tegaderm™ CHG dressing. Sterile Cavilon™ No Sting Barrier Film may be used to prevent adhesive trauma. It should be carefully applied to the skin, avoiding the area

© 3M 04/20/2010 Page 3 of 7 106008QA.pdf

immediately surrounding the insertion site and where the CHG gel pad is placed. Cavilon™ No Sting Barrier Film wand applicators #3343 or #3345 are recommended for IV sites; Cavilon™ No Sting Barrier Film in spray form (3346) should not be used for IV sites. Question: How can 3M™ Tegaderm™ CHG Dressings be both Occlusive and Breathable? Answer: Tegaderm™ CHG dressing consists of a gel pad containing CHG integrated with a Tegaderm™ Transparent Film Dressing. Moisture readily passes through the gel to the cover film to be released as vapor. The Tegaderm™ film acts as a selective filter. It is a barrier to external liquids, bacteria, and viruses* and breathable, allowing water vapor, oxygen, and carbon dioxide to be easily exchanged. *(In vitro testing shows that Tegaderm™ CHG provides a viral barrier from viruses 27 nm in diameter (e.g. HCV) or larger (e.g. HBV and HIV) while the dressing remains intact without leakage.) Question: Is Tegaderm™ CHG Dressing waterproof? Answer: Yes. However, in order to prevent contamination (e.g. catheter hub) during bathing or showering, it is recommended the dressing and catheter hub be protected by covering both with a waterproof material such as 3M™ Tegaderm™ Transparent Film Roll. (A non-adherent layer between Tegaderm™ CHG dressing and Tegaderm™ Transparent Film Roll is required). Question: What is the best way to remove Tegaderm™ CHG dressing? Answer: Slowly peel the dressing from the skin, towards the insertion site using the “low and slow” removal method. To facilitate removal of the gel pad from the catheter and manufactured catheter stabilization device, use of a sterile fluid (e.g. saline, alcohol wipe or swab) is recommended. (Note: alcohol should not be used for epidural catheters.) As the gel pad adhesion is released, continue the low and slow removal method. See the Tegaderm™ CHG dressing application and removal videos at www.3m.com/tegadermchg for complete instructions, including tips for removal and when to change the dressing. Question: Can I use Tegaderm™ CHG Dressing on diaphoretic patients? Answer: Yes, Tegaderm™ CHG dressing is designed to absorb fluid, however it is not designed to absorb large quantities of fluid. Tegaderm™ CHG dressing maintains antimicrobial effectiveness in the presence of perspiration and other

© 3M 04/20/2010 Page 4 of 7 106008QA.pdf

fluids and will prevent re-growth of skin flora. See question “When do I need to change the Tegaderm™ CHG Dressing” for more information. Question: Can Tegaderm™ CHG Dressing be used on infants? Answer: Tegaderm™ CHG dressing is not recommended for use on premature infants or infants under 2 months of age. Tegaderm™ CHG dressing has not been studied on infants. Current literature about the use of CHG on premature infants suggests that use of Tegaderm™ CHG dressing on infants with under-developed skin could result in hypersensitivity or necrosis of the skin. Question: Can I use this dressing for implanted ports? Answer: Tegaderm™ CHG dressing is effective where the CHG gel pad is in contact with skin and its surrounding inhibition zone. There have been no specific clinical studies related to the use of this dressing with accessed implanted ports. Question: What other devices can Tegaderm™ CHG Dressing be used with? Answer: Tegaderm™ CHG dressing can be used with any device that would benefit from skin flora reduction. Devices at risk for microbial contamination that could benefit from Tegaderm™ CHG dressing include, but are not limited to: any intravenous, intra-arterial, epidural, and hyperdemoclysis therapies, and all dialysis catheters. Tegaderm™ CHG is designed for skin applications and not mucosal use. Question: Is Tegaderm™ CHG Dressing effective when the gel pad covers the suture wing? Answer: Tegaderm™ CHG dressing is effective where the CHG gel pad is in contact with the skin and its surrounding inhibition zone. When applied to sutured catheters and sutured devices additional antimicrobial barrier protection is provided to the suture site as well as the insertion site. Question: Can Tegaderm™ CHG Dressing be safely used with hyperbaric treatments?

3 Skin & Wound Care Division 3M Health Care 3M Center, Building 275-4W-02 St. Paul, MN 55144-1000 USA 1 800 228-3957 © 3M 04/20/2010 www.3M.com/healthcare Page 5 of 7 106008QA.pdf

Answer: There have been no specific clinical studies related to the use of Tegaderm™ CHG dressings with hyperbaric treatments. Question: Can Tegaderm™ CHG Dressing be used to treat a site infection? Answer: Tegaderm™ CHG dressing is not indicated for treatment of a suspected or known site infection. Question: Will use of the Tegaderm™ CHG Dressing cause any increase growth of drug resistant organisms? Answer: No, chlorhexidine gluconate is an antiseptic which attacks and destroys bacteria by mechanisms which do not result in growth of organisms that are resistant to antibiotics. Question: Can the gel pad be cut to create a customized dressing? Answer: 3M has not studied this application and makes no recommendation. Question: Can I use Tegaderm™ CHG Dressing on every patient? Are there any contraindications for use? Answer: Do not use this product on patients with known hypersensitivity to chlorhexidine gluconate (CHG). The use of chlorhexidine gluconate containing products has been reported to cause irritations, sensitization, and generalized allergic reactions. Do not use Tegaderm™ CHG dressings on premature infants or infants younger than 2 months of age. Use of this product on premature infants may result in hypersensitivity reactions or necrosis of the skin.

3 Skin & Wound Care Division 3M Health Care 3M Center, Building 275-4W-02 St. Paul, MN 55144-1000 USA 1 800 228-3957 © 3M 04/20/2010 www.3M.com/healthcare Page 6 of 7 106008QA.pdf

Question: What types of skin reactions can occur with the use of Tegaderm™ CHG Dressing? Answer: Skin reactions seen with transparent film dressings can often be prevented by appropriate application of skin antiseptics and skin protectants, as well as correct application and removal of the dressing. Skin irritations can include:

• Contact dermatitis attributed to the transparent film dressing adhesive will present as an irritation appearing under the dressing. If the skin irritation or redness is seen not only under the dressing area but outside of the dressing, the skin reaction may be due to the chemicals in the skin prep or protectant. Failing to let the prep dry completely before covering will increase irritation.

• Skin stripping occurs when medical adhesives are removed incorrectly.

• A tension blister is a skin reaction or injury due to a mechanical force. When a film dressing is stretched into place on the skin, the film dressing has a tendency to move back into its normal shape causing skin blistering.

• Maceration is caused when the skin swells and whitens after prolonged exposure to moisture. This may occur when the dressing has not been protected during bathing or showering, or when the Tegaderm™ CHG gel pad has become oversaturated and left on the skin.

Question: How do I know if a patient has skin maceration? Answer: The outermost layer of the skin, the stratum corneum, will appear whitish and swollen, and has been softened from absorbing too much water. It is often called “bathtub skin”. Some clinicians have described this as appearing “white; yeasty; or cheesy.” Question: What should I do if I see skin maceration under the Tegaderm™ CHG Dressing gel pad? Answer: Clinicians should remove the dressing and allow the site to dry. The maceration usually resolves within a day or so with conservative treatment. Interventions that have been reported to successfully resolve skin maceration:

a. Remove the Tegaderm™ CHG dressing.

3 Skin & Wound Care Division 3M Health Care 3M Center, Building 275-4W-02 St. Paul, MN 55144-1000 USA 1 800 228-3957 © 3M 04/20/2010 www.3M.com/healthcare Page 7 of 7 106008QA.pdf

b. Clinicians should be advised to use caution in cleaning the site with CHG or alcohol, as it may cause skin irritation. Cleaning the site with another antiseptic agent, such as alcohol/ povidone iodine or povidone iodine may be preferred.

c. Use gauze and tape or an island dressing to cover the site. Change the dressing every 24-48 hours.

d. Once resolved, some clinicians have been able to resume the use of the Tegaderm™ CHG dressing without further incident.

Question: Are there any specific conditions that can contribute to excess moisture accumulation under the Tegaderm™ CHG Dressing? Answer: Contributing factors may include:

• Showering - If the dressing is not protected adequately or the dressing is not intact, any water that is allowed to leak under the dressing will be absorbed into the gel pad.

• Diaphoresis – moisture from diaphoresis or other conditions such as excessive sweat, or third spacing where the patient exhibits signs of extracellular fluids, will be absorbed into the gel pad.

• Highly exudative sites - The gel pad will absorb drainage, but is not designed to absorb large quantities of fluid.

The Tegaderm™ CHG dressing should be changed if the gel pad becomes overly swollen (see question “When do I need to change the Tegaderm™ CHG Dressing?”) For More Information Visit our website at www.3m.com/skinhealth, contact your 3M Health Care Representative, or call the 3M Health Care Customer Helpline at 1-800-228-3957. These products can be ordered from your local distributor. Outside the United States, contact your local 3M subsidiary.

IV Care Solutions

All you need, all in one.

All you need, all in one.

Every site presents the potential for infection, dislodgement, skin damage, and other complications. You need evidence-based products and protocols to minimize the risks of vascular access complications and help you achieve better patient outcomes.

3M™ Tegaderm™ CHG I.V. Securement Dressing is the only transparent dressing cleared by the FDA and proven to reduce catheter-related bloodstream infections (CRBSI) and vascular catheter colonization that aligns with evidence-based guidelines and practice standards.

• Infection Reduction• Site Visibility• Consistent Application• Catheter Securement

2

•

Infection ReductionClinically proven to reduce CRBSIs by 60% in patients with central and arterial lines;1 is active immediately and maintains consistent levels of antimicrobial activity for 10 days2

Site VisibilityTransparent dressing and gel pad enable early identification of complications at the insertion site

Catheter SecurementDesigned to minimize catheter movement and dislodgement

3

Consistent ApplicationThe integrated CHG gel pad and dressing are designed to ensure standardized, correct application3

Intraluminal; contaminations transferred to the hub from environment

Extraluminal; contaminations originate at the insertion site

Contaminations are caused by extraluminal sources (bacteria originating on the surface of the skin and growing along the outside of the catheter), by intraluminal sources (bacteria transferred to the hub or connector from environmental factors) with the remaining coming from other sources.4

CHG skin preps are used to minimize contamination of the insertion site, but microbes penetrate the skin deeper than the skin preps, and regrowth can occur within 24 hours.5

3M™ Tegaderm™ I.V. Securement Dressings protect against extraluminal contamination and are proven to reduce CRBSI and vascular catheter colonization.

Clinically proven to reduce CRBSI.

Skin

Vein

4

Align your protocols with standards of practice. The Centers for Disease Control and Prevention (CDC), Infusion Nurses Society (INS), Association for Professionals in Infection Control and Epidemiology (APIC), Society for Healthcare Epidemiology of America (SHEA), and other organizations offer evidence-based best practices to help minimize I.V. site complications. Choose 3M™ Tegaderm™ CHG I.V. Securement Dressings and be sure you’re meeting or exceeding best practices for better patient and economic outcomes.

CatheterSecurementThe CDC and Infusion Therapy Standards of Practice recommend the use of sutureless securement devices to minimize the risks of movement, dislodgement, and needlestick injuries.6,10

Site VisibilityThe CDC and Infusion Therapy Standards of Practice recommend the use of transparent dressings because they permit continuous visual inspection of the catheter site.6,10

5

Consistent ApplicationThe International Organization of Standards promote the importance of medical device design to support correct use, patient safety, user satisfaction and to reduce medical device-related errors.11

Infection ReductionAPIC, INS and the SHEA Compendium recommend CHG-impregnated dressings.6,7,8 In use for over 50 years, CHG has proven to be an effective antimicrobial. Bacterial resistance to CHG has been rare.9

Jugular

6

Choose the dressing that’s right for you. 3M™ Tegaderm™ CHG Dressings come in multiple sizes and shapes to accommodate a variety of sites and central vascular access devices (CVAD).

Femoral

Arterial

PICC

Subclavian

Peripheral

Implanted port

7

Inspired by you.Over the last 35 years clinicians have come to rely on Tegaderm™ transparent film dressings. Since then, we’ve listened, we’ve learned, and we’ve responded.

We’ve applied science in creative ways to:• Create dressings that are more comfortable • Make it easier for clinicians to provide reliable antimicrobial protection• Ensure catheters stay in place without causing undue pain or distress

3M™ Tegaderm™ Chlorhexidine Gluconate (CHG) I.V. Securement Dressing

The only transparent dressing proven to reduce CRBSI and vascular catheter colonization. The gel pad provides 2% CHG to the skin surface immediately, without requiring moisture to activate. The integrated design ensures consistent application, aligning with evidence-based guidelines and practice standards.

The full line of Tegaderm™ CHG Dressings may be worn up to 7 days and provide:

• CHG antimicrobial protection• Secure adhesion• Gentle removal• I.V. site visibility• Breathability• Patient comfort

88

3M™ PICC/CVC Securement Device + Tegaderm™ CHG I.V. Securement Dressing

An engineered stabilization device (ESD) plus antimicrobial (CHG) dressing designed to provide continuous antimicrobial protection for up to 7 days.

3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Port Dressing

Antimicrobial (CHG) gel pad plus I.V. port dressing specifically designed to protect single or double implanted venous ports and non-coring “Huber” needles from pathogens most commonly found in CRBSIs.*

* in vitro studies show the CHG gel pad is a microbial barrier and protects the insertion site against a variety of gram-positive and gram-negative bacteria and yeast, including organisms most commonly associated with catheter-related bloodstream infections (CRBSI). 3M data on file (010659).

I.V. port dressing

CHG gel padCHG I.V. securement dressing

Sutureless securement device

99

See the evidence for yourself.

Proven to reduce catheter-related bloodstream infections (CRBSI) and vascular catheter colonization1

in vitro tests demonstrated that the reservoir of CHG within the gel pad was as available and as effective at Day 10 as Day 1.

Offers consistent

antimicrobial activity 2

Day 10

Day 1

The indication is based on the results of a randomized, multi-arm, controlled clinical trial consisting of 1,879 subjects with 4,163 central venous and arterial catheters conducted at 11 hospitals that showed the use of Tegaderm™ CHG I.V. Securement Dressing reduced the incidence of CRBSI by 60% in patients with central and arterial lines.

Pairwise testing done against Tegaderm™ CHG Dressing using a paired t-test with Holm stepwise adjustment for multiple comparisons.

Maintains

than BIOPATCH® Disk 5

lower skin organism counts

Tegaderm Dressing (Control)

Tegaderm CHGDressing

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

n=31 31 31 31 31 30 30 30 30 29 30Baseline Post-Prep Day 1 Day 4 Day 7

Mea

n Lo

g C

ount

LO

G10

CFU

/CM

2

BIOPATCH®

Disk

Add footnotes for * + **

* p-values < 0.01. ** represents p-values < 0.001. One subject had baseline <2.5 log10 CFU/cm2, one had dressings lost by day 4 and one lost BIOPATCH® by day 7. All pairwise testing done against Tegaderm™ CHG Dressing using a paired t-test with Holm stepwise adjustment for multiple comparisons.

****

**

*

10

* p-values < 0.01. ** represents p-values < 0.001. One subject had baseline <2.5 log10 CFU/cm2, one had dressings lost by day 4 and one lost BIOPATCH® by day 7. All pairwise testing done against Tegaderm™ CHG Dressing using a paired t-test with Holm stepwise adjustment for multiple comparisons.

The CHG gel pad can absorb blood and other fluids without compromising antimicrobial activity.

Absorbs

blood & fluids11

larger areaof antimicrobial protection

Provides a

The CHG gel pad’s unique size, shape and composition provide a greater area of antimicrobial activity than BIOPATCH® Disk.

CHG Gel Pad

BIOPATCH® Disk

Higher Percentage of CHG Applied Correctly

Applied Correctly

36%

Tegaderm™ CHG I.V. Securement Dressing BIOPATCH® CHG Disk

Applied Correctly

100%

n=120 n=128

are designed to ensure consistently correct application3

Tegaderm™ CHG I.V. Securement Dressings

Tegaderm™ CHG I.V. Securement Dressings have been the subject of several clinical studies by leading researchers in infection prevention and infusion therapy. To see more of the evidence supporting the proven performance of Tegaderm™ CHG Dressings, visit 3M.com/TegadermCHG.

11

3M Health Care Critical & Chronic Care Solutions Division2510 Conway AvenueSt. Paul, MN 55144-1000 USA

Phone 1-800-228-3957Web 3M.com/TegadermCHG

BIOPATCH is a registered trademark of ETHICON, INC.3M and Tegaderm are trademarks of 3M. Used under license in Canada. Please recycle. Printed in U.S.A.© 3M 2011, 2017. All rights reserved. 70-2009-9596-0

Product Product Number CHG Gel Pad Size Dressing Size Suggested Devices

3M™ Tegaderm™ Chlorhexidine Gluconate (CHG) I.V. Securement Dressing

1657 1 ½ in x 1 3/8 in 3 cm x 4 cm 3 1/2 in x 4 1/2 in 8,5 cm x 11,5 cm All CVCs, Arterial, Dialysis, Midline and other percutaneous devices

1658 1 ½ in x 1 3/8 in 3 cm x 4 cm 4 in x 4 3/4 in 10 cm x 12 cm Universal, other percutaneous devices

1659 1 ½ in x 2 4/5 in 3 cm x 7 cm 4 in x 6 1/8 in 10 cm x 15,5 cm All CVCs and PICCs

1660 4/5 in x 4/5 in 2 cm x 2 cm 2 3/4 in x 3 3/8 in 7 cm x 8,5 cm PIVs, Midline, Arterial, CVCs and other percutaneous devices

3M™ PICC/CVC Securement Device + Tegaderm™ CHG I.V. Securement Dressing

1877-2100 1 ½ in x 1 3/8 in 3 cm x 4 cm 3 1/2 in x 4 1/2 in 8,5 cm x 11,5 cm PICCs, CVCs and other vascular access devices

1879-2100 1 ½ in x 2 4/5 in 3 cm x 7 cm 4 in x 6 1/8 in 10 cm x 15,5 cm PICCs, CVCs and other vascular access devices

3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Port Dressing

1665 2 ⁷/16 in x 1 15/16 in 6,2 cm x 4,9 cm 4 3/4 in x 4 3/4 in 12 cm x 12 cm Implanted Venous Ports

To learn more about 3M™ Tegaderm™ CHG Dressings or to schedule a product evaluation, visit us at 3M.com/TegadermCHG, contact your 3M Critical & Chronic Care Solutions representative or call the 3M Health Care Customer Helpline at 1-800-228-3957. Outside of the United States, contact the local 3M subsidiary.

References

1. Timsit JF et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. Am J Crit Care Med. 2012; 186(12): 1272-1278 http://www.atsjournals.org/doi/pdf/10.1164/rccm.201206-1038OC.

2. Schwab D. Antimicrobial Activity of a CHG-Impregnated Gel Pad for IV Site Protection. Infusion Nurses Society (INS), May 2008.

3. Kohan C., MT, MS, CIC, Boyce J., MD. American Journal of Infection Control (AJIC); 2013; Vol 41, Issue 6, S142–S143; doi http://dx.doi.org/10.1016/j.ajic.2013.03.283

4. Bouza E, Burillo A, Munoz P. Catheter-related infections: diagnosis and intravascular treatment. Clinical Microbiology and Infection, 2002; 8(5): 265-274.

5. Bashir MH, Olson LK, Walters SA. Suppression of regrowth of normal skin flora under chlorhexidine gluconate dressings applied to chlorhexidine gluconate-prepped skin. Am J Infect Control. 2012; 40(4): 344-8.

6. Centers for Disease Control and Prevention. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011. Available at: http://www.cdc.gov/hicpac/pdf/guidelines/ bsi-guidelines-2011.pdf

7. APIC Implementation Guide: Guide to Preventing Central Line-Associated Bloodstream Infections, Association for Professionals in Infection Control and Epidemiology, Inc. (APIC) 2015.

8. Strategies to Prevent Central Line-Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update. Infect Control Hosp Epidemiol. July 2014; Vol 35, No 7.

9. Denton GW. Chlorhexidine. Taken from: Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001;321-336.

10. Infusion Nurses Society (INS). Infusion Therapy Standards of Practice. INS; 2016.

11. International Electrochemical Commission: IEC 62366-1:2015 IEC 201

12. Olson C, Heilman J. Clinical Performance of a New Transparent Chlorhexidine Gluconate Central Venous Catheter Dressing. Journal of the Association for Vascular Access. 2008; March; Vol 13, No 1; 13-19.

Ordering Information

CLINICAL EVIDENCE SUMMARY

The evidence is clear.

Chlorhexidine Gluconate (CHG)I.V. Securement Dressing

Comprehensive antimicrobial protection you can count onEvery site presents the potential for infection and other complications. You need evidence-based products and protocols to help you minimize the risks of vascular access complications and help you achieve better patient outcomes. Tegaderm™ CHG Dressings have been the subject of several clinical studies by leading researchers in infection prevention and infusion therapy. These studies demonstrate that Tegaderm™ CHG Dressings not only provide better performance and support clinical best practices, but also demonstrate in vitro efficacy against a broad range of microorganisms commonly associated with CRBSIs.

TEGADERM™ CHG DRESSING

Comprehensive Protection:Tegaderm™ CHG Dressings demonstrate in vitro antimicrobial efficacy against a broad range of microorganisms commonly associated with CRBSIs. (page 3)

The evidence shows that:

Tegaderm™ CHG Dressings provide consistently comprehensive antimicrobial protection.

Suppresses Regrowth:At 7 days, Tegaderm™ CHG Dressings suppress skin flora better than BIOPATCH® Disks. (page 5)

Complete Site Coverage:Tegaderm™ CHG Dressings provide antimicrobial protection under the catheter without requiring moisture. (page 6)

Continuous Antimicrobial Activity:Tegaderm™ CHG Dressings are proven to be as effective as or better than BIOPATCH® Disks at progressive kill of microflora. (page 4)

Consistently Correct Application:In a clinical audit, Tegaderm™ CHG Dressings were correctly applied of the time. (page 7)

Day 1

10Day

3M™ Tegaderm™ CHG Dressing Clinical Evidence Summary | 2

Growth Inhibition of Microorganisms Involved in Catheter-Related Infections by an Antimicrobial Transparent I.V. Dressing Containing Chlorhexidine Gluconate (CHG)

J.P. Hensler, 3M Health Care, et al. Published: European Society of Clinical Microbiology and Infectious Diseases (ECCMID), May 2009.

STUDY TYPE: In vitro PURPOSE: To evaluate the antimicrobial activity of the transparent dressing 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing against microorganisms commonly associated with catheter-related (CR) infections using in vitro zone of inhibition.

KEY FINDINGS:• Tegaderm™ CHG Dressings demonstrated in vitro antimicrobial efficacy against

a broad range of microorganisms commonly associated with CRBSIs.

• Many of the 37 strains tested were resistant organisms, including MRSA, MRSE, VRE, and MDR strains.

• Tegaderm™ CHG Dressings retain their antimicrobial properties over time as demonstrated by the aged dressing’s ability to produce similar zones of inhibition compared to unaged dressings.

COMPREHENSIVE PROTECTION

Tegaderm™ CHG Dressings provide comprehensive antimicrobial protection

INCLUDING GRAM POSITIVE BACTERIA, GRAM NEGATIVE BACTERIA AND YEAST.

37 strains of microorganisms

Pseudomonas aeruginosa (5 strains)

Enterobacter (1 strain)

Escherichia coli (1 strain)

Enterococcus (5 strains)

Klebsiella (2 strains)

Staphylococcus aureus (8 strains)

Candida (2 strains)

Other (6 strains)

Coag Neg Staph (7 strains)

Tegaderm™ CHG Dressings demonstrates in vitro efficacy against

3M™ Tegaderm™ CHG Dressing Clinical Evidence Summary | 3

CONTINUOUS ANTIMICROBIAL ACTIVITY

A Novel Integrated Chlorhexidine-impregnated Transparent Dressing for Prevention of Vascular Catheter-related Bloodstream Infection: A Prospective Comparative Study in Healthy Volunteers

Dr. Dennis Maki, University of Wisconsin School of Medicine and Public Health, et al. Published: The Society for Health Care Epidemiology of America, April 2008.

Tegaderm™ CHG Dressings provide continuous antimicrobial activity

Provides Immediate and Persistent Reduction of Microbes

0 1 2 3 4 5 6 7 8 9 10

3.5

3.0

2.5

2.0

1.5

1.0

0.5

0.0

Tegaderm™ CHG Dressing BIOPATCH® Disk

Days

Mic

roflo

ra C

ount

(Log

CFU

/CM

3 + S

EM)

In vivo kill time of normal flora on unprepped skin on healthy adult volunteers (P=0.08)

STUDY TYPE: Clinical study PURPOSE: To compare the antimicrobial effectiveness of Tegaderm™ CHG Dressings vs. BIOPATCH® Disks.

KEY FINDINGS:• Tegaderm™ CHG Dressings are proven to be as effective as or better than

BIOPATCH® Disks at persistently reducing microbes at each time point.

3M™ Tegaderm™ CHG Dressing Clinical Evidence Summary | 4

Suppression of Regrowth of Normal Skin Flora Under Chlorhexidine Gluconate (CHG) Dressings Applied to CHG-Prepped Skin

M.H. Bashir, MICROBIOTEST, Inc., et al. Published: American Society for Microbiology (ICAAC) and Infectious Diseases Society of America (IDSA), October 2008.

SUPPRESSES REGROWTH

Tegaderm™ CHG Dressings suppress regrowth better than BIOPATCH® on prepped skin

STUDY TYPE: Randomized clinical trial PURPOSE: To compare the skin organism suppression performance of Tegaderm™ CHG Dressings vs. BIOPATCH® Disks.

KEY FINDINGS:• Skin organisms remain and will regrow even after prepping with a CHG prep.

• Tegaderm™ CHG Dressings had significantly lower skin organism regrowth than a standard transparent adhesive dressing.

• At 7 days, Tegaderm™ CHG Dressings had significantly lower skin organism regrowth than BIOPATCH® Disks.

Tegaderm™ CHG Dressing BIOPATCH® Disk Tegaderm™ Dressing (Control)

n=31 31 31 31 31 30 30 30 30 29 30

3.5

3.0

2.5

2.0

1.5

1.0

0.5

0.0

Baseline Post-Prep Day 1 Day 4 Day 7

Mea

n Sk

in O

rgan

ism

Log

Cou

nt (L

OG10

CFU

/CM

2 )

**

***

**

All pairwise testing done against Tegaderm CHG Dressing using a paired t-test with Holm stopwise adjustment for multiple comparisons.* p-values <0.01 ** represents p-value <0.001

Maintains Lower Skin Organism Counts

Mean skin organism log count over time

3M™ Tegaderm™ CHG Dressing Clinical Evidence Summary | 5

COMPLETE SITE COVERAGE

Antimicrobial Activity of a CHG-Impregnated Gel Pad for I.V. Site Protection

Debra Schwab, 3M Senior Research Microbiologist, et al. Published: Infusion Nursing Society, May 2008.

Tegaderm™ CHG Dressings provide antimicrobial protection under the catheter

STUDY TYPE: In vitro PURPOSE: To compare the in vitro antimicrobial effectiveness of Tegaderm™ CHG Dressings to that of BIOPATCH®.

KEY FINDINGS:• The Tegaderm™ CHG gel pad provides antimicrobial protection without any additional moisture.

• CHG from the Tegaderm™ CHG Dressings diffused under the catheter.

Provides Antimicrobial Protection under the Catheter

Images of agar plates innoculated with S. epidermidis

Day 3Experiment Setup Day 1

Provides Antimicrobial Protection without Moisture

Images of agar plates innoculated with S. epidermidis at 24 hours

Control

The darker zone in the center of the Tegaderm™ CHG Dressing photo demonstrates bacterial inhibition.

Tegaderm™ CHG Dressing BIOPATCH® Disk

The darker zone demonstrates bacterial inhibition under and around the catheter.

The imprint left by the gel pad is visible in the photo.

3M™ Tegaderm™ CHG Dressing Clinical Evidence Summary | 6

Higher Percentage of Dressings Correctly Applied

STUDY TYPE: Clinical audit PURPOSE: To evaluate frequency of correct application for BIOPATCH® CHG sponge dressings and Tegaderm™ CHG gel dressings by auditing 248 dressing applications.

KEY FINDINGS:• BIOPATCH® Disks were placed incorrectly 64% of the time despite repeated educational

sessions provided to staff responsible for inserting and dressing the catheters.

• Inappropriate placement of the BIOPATCH® Disks included the disk placed on top of the catheter, disk upside down, radial slit not approximated, or disk too small for catheter size.

• Tegaderm™ CHG Dressings were placed correctly in 100% of cases with the CHG gel pad completely covering the insertion site.

• Using Tegaderm™ CHG Dressings, the proportion of insertion sites improperly dressed decreased, and the CHG maintained contact with the patients’ skin.

CONSISTENTLY CORRECT APPLICATION

A Different Experience with Two Different Chlorhexidine Gluconate Dressings for use on Central Venous Devices

Cynthia A. Kohan, MT, MS, CIC, John M. Boyce, MD. Published: American Journal of Infection Control (AJIC); 2013; Vol 41, Issue 6, S142–S143; doi http://dx.doi.org/10.1016/j.ajic.2013.03.283

Tegaderm™ CHG Dressings are designed to ensure consistently correct application

Applied Correctly

36%

Tegaderm™ CHG Dressing BIOPATCH® CHG Disk

Applied Correctly

100%

n=120 n=128

3M™ Tegaderm™ CHG Dressing Clinical Evidence Summary | 7

Clinical Evidence

1 Growth Inhibition of Microorganisms Involved in Catheter-Related Infections by an Antimicrobial Transparent IV Dressing Containing Chlorhexidine Gluconate (CHG): J.P. Hensler, 3M Health Care, et al. Published: European Society of Clinical Microbiology and Infectious Diseases (ECCMID), May 2009. [70-2010-7286-8]

2 Antimicrobial Activity of a Chlorhexidine Intravascular Catheter Site Gel Dressing: Tarja Karpanen, Anna L Casey, Barbara R Conway, Tom S J Elliott. J Antimicrob Chemother. 2011 Aug;66(8):1777-84. doi: 10.1093/jac/dkr191.

2 3 A Novel Integrated Chlorhexidine-impregnated Transparent Dressing for Prevention of Vascular Catheter-related Bloodstream Infection: A Prospective Comparative Study in Healthy Volunteers: Dr. Dennis Maki, University of Wisconsin School of Medicine and Public Health, et al. Published: The Society for Health Care Epidemiology of America, April 2008. [70-2009-9686-9]

2 4 Antimicrobial Activity of a CHG-Impregnated Gel Pad for IV Site Protection: Debra Schwab, 3M Senior Research Microbiologist, et al. Published: Infusion Nursing Society, May 2008. [70-2009-9694-3]

3 Suppression of Regrowth of Normal Skin Flora Under Chlorhexidine Gluconate (CHG) Dressings Applied to CHG-Prepped Skin: M.H. Bashir, MICROBIOTEST, Inc., et al. Published: American Society for Microbiology (ICAAC) and Infectious Diseases Society of America (IDSA), October 2008. [70-2010-7144-9]

4 Migration of Chlorhexidine Gluconate Under Antimicrobial Gel Pad of IV Securement Dressing to Provide Continual Antimicrobial Protection: Debra Schwab, 3M Senior Research Microbiologist, et al. Published: Association for Vascular Access, September 2008. [70-2010-7089-6]

5 Evaluation of a New CHG Gel Pad Dressing for Catheter Care: Cindy Zehrer, RN, MS, 3M Health Care, et al. Published: Infusion Nursing Society, May 2009. [70-2010-7280-1]

5 A Multicenter Prospective Open Label Evaluation of the Clinical Performance of a Chlorhexidine Gluconate Antimicrobial Transparent Dressing: Mary Deschneau, RN, BSN, 3M Health Care, et al. Published: Infusion Nursing Society, May 2008. [70-2009-9692-7]

4 5 Clinical Performance of a New Transparent Chlorhexidine Gluconate Central Venous Catheter Dressing: Carol Olson, RN-BC and the Vascular Access Team of Abbott Northwestern Hospital. Journal of the Association for Vascular Access (JAVA); March 2008; Vol 13 No 1; 13-19. [70-2009-9669-5]

5 Prospective, Randomized, Controlled Trial Assessing the Clinical Performance of a Transparent Chlorhexidine Gel Pad Intravascular Catheter Dressing: Dr. Mark Rupp, University of Nebraska Medical Center, et al. Published: The Society for Health Care Epidemiology of America, April 2008. [70-2009-9687-7]

5 A Different Experience with Two Chlorhexidine Gluconate Dressings for Use on Central Venous Devices: Cynthia A. Kohan, MT, MS, CIC, John M. Boyce, MD. American Journal of Infection Control (AJIC); 2013; Vol 41, Issue 6, S142–S143; doi http://dx.doi.org/10.1016/j.ajic.2013.03.283

5 The Use of Chlorhexidine Gluconate (CHG) on Central Line Insertion Sites: Disk versus Gel Pad Dressing: Susanne Meninger RN, BSN, Floating Hospital for Children at Tufts Medical Center, et al. Published: Association for Vascular Access, September 2009.

5 The Absorptive Abilities of the Tegaderm™ CHG Dressing: Can Initial Gauze Dressings Be Avoided?: Carol Olson, RN-BC, The Vascular Access Team of Abbott Northwestern Hospital. Published: The Society for Health Care Epidemiology of America, March 2009. [70-2010-7261-1]

5 A Controlled Randomized Prospective Comparative Study to Evaluate the Ease of Use of a Transparent Chlorhexidine Impregnated Gel Dressing Versus A Chlorhexidine Disk in Healthy Volunteers: Chou I. Eyberg B.S., B.S.Ch.E., M.S., and Janine Pyrek, B.S., M.S., Journal of the Association for Vascular Access (JAVA). Fall 2008; Vol 13 No 3; 112-117.

COMPREHENSIVE PROTECTION1 CONTINUOUS

ANTIMICROBIAL ACTIVITY2 SUPPRESSES REGROWTH3 CONSISTENTLY

CORRECT APPLICATION5

3M Health Care Critical & Chronic Care Solutions Division2510 Conway AvenueSt. Paul, MN 55144-1000 USA

Phone 1-800-228-3957Web 3M.com/TegadermCHG

3M CanadaP.O. Box 5757 London, Ontario N6A 4T1 Canada

Phone 1-800-364-3577Web 3M.ca/HealthCare

BIOPATCH is a registered trademark of ETHICON, INC.3M and Tegaderm are trademarks of 3M. Used under license in Canada. Please recycle. Printed in U.S.A.© 3M 2009, 2016. All rights reserved. 70-2010-7513-5

To learn more about 3M™ Tegaderm™ CHG Dressings or to schedule a product evaluation, visit us at 3M.com/TegadermCHG

COMPLETE SITE COVERAGE4

BioPatch® Disks with CHG

n=128

Applied Correctly

36%

Tegaderm™ CHG IV Securement Dressings

n=120

Applied Correctly

100%

Tegaderm™ CHG IV Securement Dressing is the only transparent

dressing cleared and proven to reduce catheter-related

bloodstream infections (CRBSIs).

Product Comparison

vs.

Are your patients clearly protected against CRBSI?

Chlorhexidine Gluconate (CHG)I.V. Securement Dressing

Consistent applicationHigher Percentage of CHG Correctly Applied²

in a randomized control trial (RCT) of 1,879 subjects with 4,163 catheters.1

60% reduction of CRBSIs

BioPatch® Disks with CHG3M™ Tegaderm™ CHG Chlorhexidine Gluconate IV Securement Dressings

Comparison of Design and Performance of 2 ChlorhexidineGluconate (CHG) Containing Products

Tegaderm™ CHG IV Securement

Dressings

BioPatch®

Diskswith CHG

Infe

ctio

n Re

duct

ion

Cleared and clinically proven to reduce CRBSIs Shown to reduce CRBSIs in multiple randomized controlled trials. ● ●

Proven to reduce CRBSIs in the largest RCT on CHG dressings Tegaderm™ CHG IV Securement Dressings reduced CRBSIs by 60% in a randomized controlled trial of 1,879 subjects with 4,163 central venous and arterial catheters.1

●

Superior skin flora kill rate Tegaderm™ CHG Dressings are proven to be more effective than BioPatch® Disks with CHG at each time point testedover 10 days.3

●

Superior skin flora regrowth suppression over 7 days Tegaderm™ CHG Dressings are more effective at suppressing the regrowth of skin flora on prepped skin than BioPatch® Disks with CHG.4

●

Effective on skin surface beneath the catheter Chlorhexidine gluconate from the CHG gel pad or disk protects the whole area underneath the vascular catheter.5 ● ●

Suture site protection Tegaderm™ CHG IV Securement Dressings reduce the number of microorganisms at the catheter insertion site, suture site, sutures and catheter surface.*,5

●

CHG active immediately without moisture Tegaderm™ CHG IV Securement Dressings provide CHG immediately to the skin surface, regardless of the amount of skin moisture.6,7,8

●

Safe

ty &

Eas

e of

Use

Allows for constant site monitoring The 2016 Infusion Therapy Standards of Practice published by INS recommend assessing the VAD (Vascular Access Device)-skin junction site and surrounding area for redness, tenderness, swelling, and drainage by visual inspection and palpation through the intact dressing.9

●

CHG gel pad is integral to a transparent dressing Since the CHG gel pad is integral to the Tegaderm™ CHG IV Securement Dressing, it cannot be put on upside down or forgotten and eliminates the need for extra steps to apply CHG separately from the cover dressing.

●

Superior placement accuracy rate Multiple studies have shown an improved CHG placement accuracy rate with the integrated Tegaderm™ CHG IV Securement Dressing compared to the placement of a BioPatch® Disk with CHG plus a dressing.2,10

●

Integrated IV securement Tegaderm™ CHG IV Securement Dressings incorporate securement features designed to minimize catheter migration and dislodgement directly into the antimicrobial dressing.

●

Absorbs blood and fluids Can absorb up to eight times its weight in fluid and provides antimicrobial protection in the presence of perspiration, exudate and blood.11

● ●

Same dressing for any catheter Tegaderm™ CHG IV Securement Dressings do not require a minimum distance between the insertion site and the catheter hub. BioPatch® Disks with CHG require the catheter to be secured at least 0.5 inches (1.25 cm) from the insertion site to provide complete coverage.12

●

Easier to remove Tegaderm™ CHG IV Securement Dressings were rated easier to remove compared to BioPatch® Disks with CHG used with a transparent dressing.13

●

Low dermatitis potential Both Tegaderm™ CHG IV Securement Dressings and BioPatch® Disks with CHG have demonstrated skin dermatitis rates lower than 1.5%.†,1,14

● ●

Contract position with major GPOsAvailable for purchase through major Group Purchasing Organization (GPO) contracts. ● ●

Visit 3m.com/TegadermCHG for more information.

* Tegaderm CHG IV Securement Dressing is not indicated to reduce bacterial colonization of sutures or suture sites.† Not for use on premature infants or persons with known sensitivity to CHG.1. Timsit JF, et al. Randomized Controlled Trial of Chlorhexidine Dressing and Highly Adhesive Dressing for Preventing

Catheter-Related Infections in critically ill adults. American Journal of Respiratory and Critical Care Medicine 2012; 186 (12):1272-1278.

2. Cynthia A. Kohan, MT, MS, CIC, John M. Boyce, MD. Published: American Journal of Infection Control (AJIC); 2013; Vol 41, Issue 6, S142–S143; doi http://dx.doi.org/10.1016/j.ajic.2013.03.283

3. 3M Data on File (#09535).4. Bashir MH, Olson LK, Walters SA. Suppression of regrowth of normal skin flora under chlorhexidine gluconate

dressings applied to chlorhexidine gluconate-prepped skin. Am J Infect Control. 2012; 40(4): 344-8.5. Karpanen T J, Casey A L, Das I, Whitehouse T, Nightingale P, Elliott T S J, Journal of the Association for Vascular

Access 2016:September:21(3):133-138.6. Maki DG. A Novel Integrated Chlorhexidine-Impregnated Transparent Dressing for Prevention of Vascular Catheter-

related Bloodstream Infection: A Prospective Comparative Study in Healthy Volunteers. SHEA, April 2008.7. Schwab D. Antimicrobial Activity of a CHG-Impregnated Gel Pad for IV Site Protection. Infusion Nurses Society

(INS), May 2008.

8. Karpanen T, Casey A, Conway B, Lambert P, Elliott T. Antimicrobial activity of a chlorhexidine intravascular catheter site gel dressing. J Antimicrob Chemother. 2011; Aug;66(8):1777-84. doi:10.1093/jac/dkr191. Epub 2011 May 24.

9. Infusion Nurses Society (INS). Infusion Therapy Standards of Practice. INS; 2016. Standard 41C.10. Eyberg C. A Controlled Randomized Prospective Comparative Study to Evaluate the Ease of Use of a Transparent

Chlorhexidine Impregnated Gel Dressing Versus A Chlorhexidine Disk in Healthy Volunteers. Journal of the Association for Vascular Access (JAVA); 2008;13(3).

11. 3M Data on File (#10658).12. Johnson & Johnson Wound Management. (2012). The PROVEN Way to Reduce Catheter Related Blood Stream

Infections [Brochure]. N.p.: Ethicon, Inc.13. Pfaff B, Heithaus T, Emanuelsen M, Critical Care Nurse 2012; 32(4): 35-40. Use of a 1-piece chlorhexidine gluconate

transparent dressing on critically ill patients.14. Timsit JF, Schwebel C, Bouadama L, Geffroy A, Garrouste-Ogeas M,Pease S, et al. Chlorhexidine-Impregnated

Sponges and Less Frequent Dressing Changes for Prevention of Catheter-Related Infections in Critically Ill Adults: A Randomized Controlled Trial. JAMA. 2009;301(12):1231-1241.

3M Health Care Critical & Chronic Care Solutions Division2510 Conway AvenueSt. Paul, MN 55144-1000 USA

Phone 1-800-228-3957Web 3M.com/TegadermCHG

Please recycle. Printed in U.S.A. © 3M 2014, 2017. All rights reserved. 3M and Tegaderm are trademarks of 3M. BioPatch is a trademark of Ethicon. 70-2011-6976-3

Antimicrobial Protection

Catheter Securement

Skin Protection

1 × 61 × 8

16 × 9

8.5 x .5

11 × 17 (Tabloid)8

× 8 (Square)

8.5 × 11 (Letter)

Central Vascular Access Device (CVAD) Stabilization Standard 37, pages S72-73

• Do not rely on VA device dressings (standard, non-bordered transparent semipermeable membrane (TSM) dressings, gauze and tape dressings) as a means of stabilization as there is insufficient evidence supporting their benefits as stabilization devices. (Level I)

• For PIV consider: (1) Integrated stabilization on PIV catheter hub with a bordered polyurethane securement dressing or (2) a standard round hub PIV in combination with an adhesive engineered stabilization device (ESD*). (Level III)

• Use of a bordered polyurethane securement dressing alone on a PIV with a traditional hub allowed more PIVs to reach 72 hours of dwell with fewer needing restarts; however, more data are needed. (Level V)

Needleless Connectors Standard 34, page S69

• Use of passive disinfecting caps containing disinfecting agent (IPA) shown to reduce intraluminal microbial contamination and reduce rates of CLABSIs.

• Use of disinfection caps on PIVs has limited evidence but should be considered.

• Ensure disinfecting supplies are readily available at bedside to facilitate staff compliance with needleless connector disinfection. (Level V)

Central Vascular Access Device (CVAD) Stabilization Standard 37, pages S72-73

• Be aware of the risk of medical adhesive-related skin injury (MARSI) associated with the use of adhesive ESDs.

• Apply barrier solutions to skin exposed to adhesive dressing to reduce risk of Medical Adhesive Related Skin Injury (MARSI). (Level I)

2016 Updates to the INS Infusion Therapy Standards of Practice

3MSM Health Care Academy 2016 Infusion Therapy Standards of Practice overview modules available at 3M.com/3MHealthCareAcademy

* Engineered Stabilization Device (ESD): A device or system placed subcutaneously or topically; specifically designed and engineered to control movement at the catheter hub.

Gorski L, Hadaway L, Hagle ME, McGoldrick M, Orr M, Doellman D. Infusion therapy standards of practice. J Infus Nurs. 2016; 39(suppl 1):S1-S159.

Peripheral Lines

Catheter Securement

Skin Protection

Antimicrobial Protection

3M™ Tegaderm™ I.V. Advanced Securement Dressing• Engineered Stabilization Device (ESD) system designed

with securement dressing and borders, stability notch, and securement strips

• Promotes consistent application

• Provides securement and barrier to external contaminants*

3M™ Curos™ Disinfecting Caps• Consistent use of Curos™ Disinfecting Caps on I.V. needleless

connectors is associated with decreased CLABSI

• Strips hang on I.V. poles, positioning caps for convenient, bedside availability

3M™ Cavilon™ No Sting Barrier Film• Proven to protect skin from adhesive trauma (MARSI)

• Compatible with chlorhexidine gluconate (CHG)

• Provides a fast-drying, sterile solution

1 × 61 × 8

16 × 9

8.5 x .5

11 × 17 (Tabloid)8

× 8 (Square)

8.5 × 11 (Letter)

3M has solutions that can help clinicians be compliant with 2016 Infusion Therapy Standards of Practice

* in vitro testing shows that the transparent film provides a viral barrier from viruses 27nm in diameter or larger while the dressing remains intact without leakage.

3M.com/IVcare © 3M 2016. All Rights Reserved.70-2011-5789-1

Peripheral Lines